Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

Contributed by: PR Newswire

Tags

Simcere-Sanbexin

More Like This

PR Newswire associated0

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

PR Newswire associated0

Simcere Phar-maceuticals Presented Six Studies on Sanbexin® at ESOC 2024

New Study Demonstrates that SL-NAD+ delivers NAD+ into Cells

PR Newswire associated0

VST BIO Announces Groundbreaking Data from Non-Human Primate Study Evaluating Novel Monoclonal Antibody to Treat Ischemic Stroke at AHA International Stroke Conference

PR Newswire associated0

Daewoong Pharmaceutical's Bersiporocin Receives 'Orphan Drug Designation' in Europe to Treat Idiopathic Pulmonary Fibrosis

Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA

PR Newswire associated0

Onconic Therapeutics Announces Positive Phase 3 Results for JAQBO at Digestive Diseases Week 2024

Submission of Leqembi® (lecanemab-irmb) sBLA for IV maintenance dosing for the treatment of early Alzheimer's disease to the U.S. FDA completed